Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 270

The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.

Ursodeoxycholic acid for primary biliary cirrhosis

Open access
Rudic, Jelena S, Poropat, Goran, Krstic, Miodrag N, Bjelakovic, Goran, Gluud, Christian·2012·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Ursodeoxycholic acid is administered to patients with primary biliary cirrhosis, a chronic progressive inflammatory autoimmune-mediated liver disease with unknown aetiology. Despite its controversial effects, the U.S. Food and Drug Administration has approved its usage for primary biliary cirrhosis. OBJECTIVES: To assess the beneficial and harmful effects of ursodeoxycholic acid in patients with primary biliary cirrhosis. SEARCH METHODS: We searched for eligible randomised trials in The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, LILACS, Clinicaltrials.gov, and the WHO International Clinical Trials Registry Platform. The literature search was performed until January 2012. SELECTION CRITERIA: Randomised clinical trials assessing the beneficial and harmful effects of ursodeoxycholic acid versus placebo or 'no intervention' in patients with primary biliary cirrhosis. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data. Continuous data were analysed using mean difference (MD) and standardised mean difference (SMD). Dichotomous data were analysed using risk ratio (RR). Meta-analyses were conducted using both a random-effects model and a fixed-effect model, with 95% confidence intervals (CI). Random-effects model meta-regression was used to assess the effects of covariates across the trials. Trial sequential analysis was used to assess risk of random errors (play of chance). Risks of bias (systematic error) in the included trials were assessed according to Cochrane methodology bias domains. MAIN RESULTS: Sixteen randomised clinical trials with 1447 patients with primary biliary cirrhosis were included. One trial had low risk of bias, and the remaining fifteen had high risk of bias. Fourteen trials compared ursodeoxycholic acid with placebo and two trials compared ursodeoxycholic acid with 'no intervention'. The percentage of patients with advanced primary biliary cirrhosis at baseline varied from 15% to 83%, with a median of 51%. The duration of the trials varied from 3 to 92 months, with a median of 24 months. The results showed no significant difference in effect between ursodeoxycholic acid and placebo or 'no intervention' on all-cause mortality (45/699 (6.4%) versus 46/692 (6.6%); RR 0.97, 95% CI 0.67 to 1.42, I² = 0%; 14 trials); on all-cause mortality or liver transplantation (86/713 (12.1%) versus 89/706 (12.6%); RR 0.96, 95% CI 0.74 to 1.25, I² = 15%; 15 trials); on serious adverse events (94/695 (13.5%) versus 107/687 (15.6%); RR 0.87, 95% CI 0.68 to 1.12, I² = 23%; 14 trials); or on non-serious adverse events (27/643 (4.2%) versus 18/634 (2.8%); RR 1.46, 95% CI 0.83 to 2.56, I² = 0%; 12 trials). The random-effects model meta-regression showed that the risk of bias of the trials, disease severity of patients at entry, ursodeoxycholic acid dosage, and trial duration were not significantly associated with the intervention effects on all-cause mortality, or on all-cause mortality or liver transplantation. Ursodeoxycholic acid did not influence the number of patients with pruritus (168/321 (52.3%) versus 166/309 (53.7%); RR 0.96, 95% CI 0.84 to 1.09, I² = 0%; 6 trials) or with fatigue (170/252 (64.9%) versus 174/244 (71.3%); RR 0.90, 95% CI 0.81 to 1.00, I² = 62%; 4 trials). Two trials reported the number of patients with jaundice and showed a significant effect of ursodeoxycholic acid versus placebo or no intervention in a fixed-effect meta-analysis (5/99 (5.1%) versus 15/99 (15.2%); RR 0.35, 95% CI 0.14 to 0.90, I² = 51%; 2 trials). The result was not supported by the random-effects meta-analysis (RR 0.56, 95% CI 0.06 to 4.95). Portal pressure, varices, bleeding varices, ascites, and hepatic encephalopathy were not significantly affected by ursodeoxycholic acid. Ursodeoxycholic acid significantly decreased serum bilirubin concentration (MD -8.69 µmol/l, 95% CI -13.90 to -3.48, I² = 0%; 881 patients; 9 trials) and activity of serum alkaline phosphatases (MD -257.09 U/L, 95% CI -306.25 to -207.92, I² = 0%; 754 patients, 9 trials) compared with placebo or no intervention. These results were supported by trial sequential analysis. Ursodeoxycholic acid also seemed to improve serum levels of gamma-glutamyltransferase, aminotransferases, total cholesterol, and plasma immunoglobulin M concentration. Ursodeoxycholic acid seemed to have a beneficial effect on worsening of histological stage (random; 66/281 (23.5%) versus 103/270 (38.2%); RR 0.62, 95% CI 0.44 to 0.88, I² = 35%; 7 trials). AUTHORS' CONCLUSIONS: This systematic review did not demonstrate any significant benefits of ursodeoxycholic acid on all-cause mortality, all-cause mortality or liver transplantation, pruritus, or fatigue in patients with primary biliary cirrhosis. Ursodeoxycholic acid seemed to have a beneficial effect on liver biochemistry measures and on histological p

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd000551.pub3

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 141 references

Research works printed but not linked: 85

  1. Italian Multicenter Project for UDCA Treatment in PBC, 1989, Ursodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): a double-blind multicenter trial (EASL abstract), Journal of Hepatology, 9, 87
  2. Podda M Almasio P Battezzati PM Crosignani A and Italian Multicenter Group for the Study of UDCA in PBC Long-term effect of the administration of ursodeoxycholic acid alone or with colchicine in patients with primary biliary cirrhosis: a double-blind multicenter study Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68 1993 310 5
  3. Podda, 1989, Urodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): a double-blind multicenter trial [AASLD abstract], Hepatology, 10, 639
  4. Carithers, 1996, Extended follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis (Abstract), Gastroenterology, 110, A1163
  5. Combes, 1991, Ursodeoxycholic acid therapy in patients with primary biliary cirrhosis [AASLD abstract], Hepatology, 14, 91A
  6. Combes, 1993, A randomised, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (AASLD Abstract), Hepatology, 18, 175A, 10.1016/0270-9139(93)92227-Q · doi:10.1016/0270-9139(93)92227-q
  7. Combes B Carithers RL Maddrey WC Munoz SJ McDonald MF Garcia-Tsao G A randomised, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) Falk Symposium No. 68. XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel 1992 43
  8. Combes B Carithers RL Maddrey WC Munoz SJ McDonald MF Garcia-Tsao G A randomised, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68 1993 289 91
  9. Combes B Carithers RL Maddrey WC Munoz SJ McDonald MF Garcia-Tsao G The American multicenter primary biliary cirrhosis, Ursodiol versus placebo study group (PUPS) trial Falk Symposium No. 80. XIII International Bile Acid Meeting. Bile Acids in Gastroenterology: Basic and Clinical Aspects. San Diego 1994 67
  10. Emond, 1996, Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the US multicenter trial to expected survival using the Mayo Clinic prognostic model [AASLD abstract], Hepatology, 24, 168A
  11. Mora, 1994, Does treatment with ursodeoxycholic acid (UDCA) really diminish cholesterol serum levels in primary biliary cirrhosis (PBC)? [EASL abstract], Hepatology, 19, 57I, 10.1016/0270-9139(94)90396-4 · doi:10.1016/0270-9139(94)90396-4
  12. Eriksson, 1995, Ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) Results of a two-year randomised placebo-controlled study (abstract), Scandinavian Journal of Gastroenterology, 30, 35
  13. Goddard, 1994, A trial of ursodeoxycholic acid (UDCA) and colchicine in primary biliary cirrhosis (PBC) (AASLD abstract), Hepatology, 20, 151A
  14. Goddard, 1995, Surrogate markers of response in a trial of ursodeoxycholic acid (UDCA) and colchicine in primary biliary cirrhosis (PBC), Gut, 36, A30
  15. Heathcote EJL Cauch K Walker V Bailey RJ Blendis LM Ghent CN A double blind randomised controlled multi-centre trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC): results from a blinded interim analysis XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel. Falk Symposium No. 68 1992 45
  16. Heathcote, 1992, The Canadian multi-centre double blind randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis [AASLD abstract], Hepatology, 16, 91A
  17. Heathcote, 1993, A four-year follow-up study of ursodeoxycholic acid therapy for primary biliary cirrhosis, Gastroenterology, 104, A914
  18. Heathcote EJL Cauch K Walker V Blendis LM Pappas SC Wanless IR A double-blind randomised controlled multicenter trial of ursodeoxycholic acid in primary biliary cirrhosis: results from a 1991 interim analysis Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68 1993 294 8
  19. Kilmurry, 1995, Is the Mayo model useful for predicting survival following the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? [abstract], Gastroenterology, 108, 96
  20. Michieletti, 1993, No evidence for a more atherogenic serum lipid profile with ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cirrhosis (PBC) [abstract], Hepatology, 18, 217A, 10.1016/0270-9139(93)92390-L · doi:10.1016/0270-9139(93)92390-l
  21. Neuman MG Cameron RG Shear NH Blendis LM Ursodeoxycholic acid reduces fibrosis in primary biliary cirrhosis (Abstract) XV International Bile Acid Meeting. Bile Acids and Cholestasis. Titisee, Germany. Falk Symposium No 108 1998 59
  22. Güldütuna, 1992, Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid, Zeitschrift fur Gastroenterologie, 30 Suppl 1, 49
  23. Leuschner M Güldütuna S Imhof M Bhati S You T Leuschner U Ursodeoxycholic acid therapy in primary biliary cirrhosis Bile acids and the hepatobiliary system. From Basic Science to Clinical Practice. Falk Symposium 68 1993 299 302
  24. Leuschner, 1989, Does ursodeoxycholic acid (UDCA) influence cell membrane architecture in patients with primary biliary cirrhosis (PBC)?, Gastroenterology, 96, A621
  25. Leuschner U Fisher H Hübner K Güldütuna S Gatzen M Hellstern A Ursodeoxycholic acid (UDCA) treatment of primary biliary cirrhosis: clinical and histological results of a controlled study Trends in Bile Acid Research. Falk Symposium 52 1989 355 8
  26. Dickson ER Lindor KD Beneficial effects of ursodeoxycholic acid in an open trial of patients with primary biliary cirrhosis Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Falk Symposium 58 1991 271 2
  27. Dickson ER Lindor KD Baldus WP Jorgensen RA Ludwig J Murtaugh PA Ursodiol (URSO) is effective therapy for patients with primary biliary cirrhosis (PBC) Falk Symposium No. 68. XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel 1992 44
  28. Dickson ER Lindor KD Baldus WP Jorgensen RA Ludwig J Murtaugh PA Ursodiol is effective therapy for patients with primary biliary cirrhosis Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68 1993 292 3
  29. Lindor, 1992, Ursodeoxycholic acid (UDCA) is beneficial therapy for patients with primary biliary cirrhosis (PBC) [AASLD abstract], Hepatology, 16, 91A
  30. Hadziyannis SJ Hadziyannis ES Lianidou E Makris A Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: the third year of a controlled trial Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Falk Symposium 58 1990 287 96
  31. Hadziyannis, 1989, A randomised controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) [abstract], Hepatology, 10, 580
  32. Hadziyannis, 1989, A randomised controlled trial of Ursodeoxyccholic acid (UDCA) in primary biliary cirrhosis (PBC), European Journal of Clinical Investigation, 19, A15
  33. Papatheodoridis, 2000, Ursodeoxycholic-acid for primary biliary cirrhosis: final results of a 12-year prospective, randomised, controlled trial, Journal of Hepatology, 32, 40, 10.1016/S0168-8278(00)80485-7 · doi:10.1016/s0168-8278(00)80485-7
  34. Pares, 2001, Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid, Journal of Hepatology, 34, 189, 10.1016/S0168-8278(01)81572-5 · doi:10.1016/s0168-8278(01)81572-5
  35. Pares, 2001, Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis, Journal of Hepatology, 34, 187, 10.1016/S0168-8278(01)80689-9 · doi:10.1016/s0168-8278(01)80689-9
  36. Parés, 1997, Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: results of a randomised, double-blind, placebo-controlled trial (abstract), Journal of Hepatology, 26, 166
  37. Chazouilleres, 1995, Histological course of primary biliary cirrhosis (PBC) treated with ursodeoxycholic acid (UDCA) [abstract], Hepatology, 2, 125A
  38. Corpechot, 1999, A Markov model for assessment of histological progression in PBC provides evidence that UDCA therapy is effective in early stages [abstract], Hepatology, 30, 474A
  39. Huet, 1994, Long term effect of ursodeoxycholic acid (UDCA) on hepatic function and portal hypertension in primary biliary cirrhosis (PBC) [AASLD abstract], Hepatology, 20, 202A
  40. Huet PM Willems B Huet J Poupon R Effects of ursodeoxycholic acid (UDCA) on hepatic function and portal hypertension in primary biliary cirrhosis (PBC) XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel. Falk Symposium No. 68 1992 118
  41. Huet, 1990, Effects of ursodeoxycholic acid (UDCA) on hepatic function and portal hypertension in primary biliary cirrhosis (PBC) [AASLD abstract], Hepatology, 12, 907
  42. Poupon R Poupon RE The UDCA-PBC Group Ursodeoxycholic acid in the treatment of primary biliary cirrhosis Strategies for the Treatment of Hepatobiliary Diseases. Falk Symposium 53 1990 79 81
  43. Poupon R Poupon RE the UDCA-PBC Group Ursodeoxycholic acid for primary biliary cirrhosis International Lugano Symposium on Biliary Physiology and Diseases: Strategies for the Treatment of Hepatobiliary Diseases. Lugano. Falk Symposium No. 53 1989 22
  44. Poupon R the UDCA-PBC Group Ursodeoxycholic acid in the treatment of primary biliary cirrhosis First International Symposium. Trends and Discovery in Bile Acid Research. Bora-Bora (French Polynesia) 1990 123 6
  45. Poupon, 1991, A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis, Annals of Internal Medicine, 115, 48
  46. Poupon, 1990, Beneficial effect of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). Final results of the French Canadian trial [AASLD abstract], Hepatology, 12, 872
  47. Poupon, 1992, Ursodeoxycholic therapy for primary biliary cirrhosis: a four year controlled study, Hepatology, 16, 91A
  48. Poupon, 1989, Ursodeoxycholic acid (UDCA) for treatment of primary biliary cirrhosis (PBC). Interim analysis of a double-blind multicenter randomised trial, Hepatology, 10, 639
  49. Arora, 1990, Effect of ursodiol on bile acid conjugation in patients with primary biliary cirrhosis [AASLD abstract], Hepatology, 12, 994
  50. Batta, 1990, Effect of ursodiol on biliary bile acid composition and conjugation in patients with primary biliary cirrhosis, Gastroenterology, 98, A567
  51. O'Brian, 1990, Ursodiol treatment of primary biliary cirrhosis, Gastroenterology, 98, A617
  52. Senior, 1990, Effect of oral ursodiol treatment on the predicted probability of mortality in primary biliary cirrhosis, Hepatology, 12, 438
  53. Senior JR O'Brien CB Mortality risk indices as outcome measures of the effectiveness of ursodeoxycholic acid treatment of cholestatic liver diseases Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Falk Symposium 58 1991 273 85
  54. Myszor, 1990, No symptomatic or histological benefit from ursodeoxycholic acid treatment in PBC after 1 year. Controlled pilot study [IASL abstract], Hepatology, 12, 415
  55. Miettinen, 1993, Improvement of serum non cholesterol sterols may indicate retarded progression of primary biliary cirrhosis (PBC) in a randomised placebo controlled two-year trial with colchicine and ursodeoxycholic acid (AASLD abstract), Gastroenterology, 104, A954
  56. Brodanova, 1997, Ursodeoxycholic acid in the treatment of primary biliary cirrhosis, Casopis Lekaru Ceskych, 136, 215
  57. Eisenburg, 1988, Treatment of primary biliary cirrhosis with ursodeoxycholic acid. Part 2: Prospective long-term trial in 21 patients, Fortschritte der Medizin, 106, 695
  58. Ferri, 1993, Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A controlled comparison with ursodeoxycholic acid, Clinica Terapeutica, 143, 321
  59. Crippa, 1995, Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis, Clinica Terapeutica, 146, 367
  60. Idéo, 1990, Efficacy of ursodeoxycholic acid in lowering alanine aminotransferase and gamma-glutamyl transpeptidase serum levels in patients with chronic active hepatitis and primary biliary cirrhosis, Current Therapeutic Research Clinical and Experimental, 47, 62
  61. Kehagioglou, 1991, Effect of UDCA on the natural course of PBC, Journal of Hepatology, 13, S134, 10.1016/0168-8278(91)91511-E · doi:10.1016/0168-8278(91)91511-e
  62. Krzeski, 1999, Effects of ursodeoxycholic acid treatment on bilirubin concentration and survival of patients with primary biliary cirrhosis, Gastroenterologia Polska, 6, 231
  63. Larghi, 1997, Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: A pilot crossover study, Alimentary Pharmacology and Therapeutics, 11, 409, 10.1046/j.1365-2036.1997.124295000.x · doi:10.1046/j.1365-2036.1997.124295000.x
  64. Lindor, 1997, Comparison of three different doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomised trial, Hepatology, 26, 438 A
  65. Batta, 1988, Ursodeoxycholic acid improves liver function and reduces serum and urinary endogenous bile acids in primary biliary cirrhosis, Hepatology, 8, 1221A
  66. Eskreis, 1988, Ursodeoxycholic acid treatment of primary biliary cirrhosis, American Journal of Gastroenterology, 83, 1065A
  67. Ogino, 1993, Effect of ursodeoxycholic acid therapy on lymphocyte function of patients with primary biliary cirrhosis, Acta Hepatologica Japonica, 34, 306, 10.2957/kanzo.34.306 · doi:10.2957/kanzo.34.306
  68. Okuyama, 1988, A case of primary biliary cirrhosis - 4 years' treatment with 300 mg/day ursodeoxycholic acid, Acta Hepatologica Japonica, 29, 799, 10.2957/kanzo.29.799 · doi:10.2957/kanzo.29.799
  69. Podda, 1988, Ursodeoxycholic acid for chronic liver diseases, Journal of Clinical Gastroenterology, 10, S25
  70. Poupon, 1989, Ursodeoxycholic acid improves histologic features and progression of primary biliary cirrhosis, Hepatology, 10, 637
  71. Schonfeld, 1997, Serial quantitative liver function tests in patients with primary biliary cirrhosis: A prospective long-term study, Digestion, 58, 396, 10.1159/000201472 · doi:10.1159/000201472
  72. Takezaki, 1991, A case of primary biliary cirrhosis with a histological improvement after long-term therapy with ursodeoxycholic acid, IRYO Japanese Journal of National Medical Services, 45, 376
  73. Toda, 1998, Dose-dependency of effect of ursodeoxycholic acid on primary biliary cirrhosis: a randomised, double-blind controlled study, Kan-Tan-Sui (Japan), 37, 443
  74. Wirth, 1995, Subtype pattern of antimitochondrial antibodies in primary biliary cirrhosis and response to ursodeoxycholic acid, Schweizerische Medizinische Wochenschrift, 125, 750
  75. Yamazaki, 1992, A patient with asymptomatic primary biliary cirrhosis associated with eosinophilic infiltration and peripheral eosinophilia improved by the administration of ursodeoxycholic acid, Acta Hepatologica Japonica, 33, 348, 10.2957/kanzo.33.348 · doi:10.2957/kanzo.33.348
  76. Yokomori, 1996, Rapid improvement of intractable pruritus in a case with primary biliary cirrhosis by a combined therapy of ursodeoxycholic acid (UDCA) and cholestyramine (CS) - Serum bile acid analysis, Acta Hepatologica Japonica, 37, 102, 10.2957/kanzo.37.102 · doi:10.2957/kanzo.37.102
  77. Angulo, 1999, Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomised trial, Journal of Hepatology, 30, 830, 10.1016/S0168-8278(99)80136-6 · DOI · Paper page
  78. Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2011, Issue 10. Art. No.: LIVER
  79. International Conference on Harmonisation of Technical Requiements for Registration of Pharmaceuticals for Human Use, 1997, Code of Federal Regulation & ICH Guidelines
  80. Myszor, 1990, No symptomatic or histological benefit from ursodeoxycholic acid treatment in PBC after 1 year. Controlled pilot study [IASL abstract], Hepatology, 12, 415
  81. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011
  82. Sharp, 1998, Metaanalysis regression, STATA Techn Bull, 4216
  83. Siegel, 2003, Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis, Journal of Clinical Gastroenterology, 37, 183, 10.1097/00004836-200308000-00018 · DOI · Paper page
  84. Christensen, 1997, Ursodeoxycholic acid for primary biliary cirrhosis, Cochrane Database of Systematic Reviews
  85. Gluud, 1999, Ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) - a Cochrane Hepato-Biliary systematic review, Journal of Hepatology, 30, 83

Cited by

See all 270

Metadata

Authors
Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2012-12-12
Volume
2012
Issue
12
Pages
CD000551-CD000551
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2108326867
Cited by
270
References
141
FWCI
10.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ursodeoxycholic acid for primary biliary cirrhosis. https://app.cochat.ai/papers/10.1002/14651858.cd000551.pub3
The paper
Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012). Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd000551.pub3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.